Key facts
- This page summarizes Andrew Sinclair's Form 4 filing for Adicet Bio, Inc. (ACET).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Jun 2023, 17:46.
Andrew Sinclair - 01 Jun 2023 Form 4 Insider Report for Adicet Bio, Inc. (ACET)
- Reporting relationship
- Director
- Issuer ticker
- ACET
- Reported as of
- 01 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Jun 2023, 17:46:31 UTC
- Prior SEC filing
- 26 May 2023
- Next SEC filing
- 16 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Nick Harvey, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Andrew Sinclair filed Form 4 for Adicet Bio, Inc. (ACET) on 02 Jun 2023.
Change
- Previous filing in this sequence was filed on 26 May 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACET
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +5,900
- Change %
- Price
- $0.000000
- Shares after
- 5,900
- Date
- 01 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,115,385
- Date
- 01 Jun 2023
- Ownership
- See Footnote
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACET
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +26,400
- Change %
- Price
- $0.000000
- Shares after
- 26,400
- Date
- 01 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 26,400
- Exercise price
- $5.20
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.
Footnote F2
These shares are held by Abingworth Bioventures 8 LP ("ABV 8"). Abingworth Bioventures 8 GP LP ("Abingworth GP") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP ("Abingworth GP 8"), serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth GP 8) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. The Reporting Person is a Partner and Portfolio Manager of Abingworth LLP.
Footnote F3
An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV 8. The Reporting Person is a member of the investment committee of ABV 8. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV 8 to employees of Abingworth LLP, subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
Footnote F4
These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.